title: T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: prospective comparison with conventional risk markers.
abstract: BACKGROUND
  The current standard for arrhythmic risk stratification is electrophysiologic (EP) testing, which, due to its invasive nature, is limited to patients already known to be at high risk. A number of noninvasive tests, such as determination of left ventricular ejection fraction (LVEF) or heart rate variability, have been evaluated as additional risk stratifiers. Microvolt T wave alternans (TWA) is a promising new risk marker. Prospective evaluation of noninvasive risk markers in low- or moderate-risk populations requires studies involving very large numbers of patients, and in such studies, documentation of the occurrence of ventricular tachyarrhythmias is difficult. In the present study, we identified a high-risk population, recipients of an implantable cardioverter defibrillator (ICD), and prospectively compared microvolt TWA with invasive EP testing and other risk markers with respect to their ability to predict recurrence of ventricular tachyarrhythmias as documented by ICD electrograms.
  
  
  RESULTS
  Ninety-five patients with a history of ventricular tachyarrhythmias undergoing implantation of an ICD underwent EP testing, assessment of TWA, as well as determination of LVEF, baroreflex sensitivity, signal-averaged ECG, analysis of 24-hour Holter monitoring, and QT dispersion from the 12-lead surface ECG. The endpoint of the study was first appropriate ICD therapy for electrogram-documented ventricular fibrillation or tachycardia during follow-up. Kaplan-Meier survival analysis revealed that TWA (P < 0.006) and LVEF (P < 0.04) were the only significant univariate risk stratifiers. EP testing was not statistically significant (P < 0.2). Multivariate Cox regression analysis revealed that TWA was the only statistically significant independent risk factor.
  
  
  CONCLUSIONS
  Measurement of microvolt TWA compared favorably with both invasive EP testing and other currently used noninvasive risk assessment methods in predicting recurrence of ventricular tachyarrhythmias in ICD recipients. This study suggests that TWA might also be a powerful tool for risk stratification in low- or moderate-risk patients, and needs to be prospectively evaluated in such populations.
authors.affiliation: Department of Cardiology, J.W. Goethe University, Frankfurt, Germany. hohnloser@em.uni-frankfurt.de
authors.forename: S H
authors.initials: SH
authors.lastname: Hohnloser
authors.forename: T
authors.initials: T
authors.lastname: Klingenheben
authors.forename: Y G
authors.initials: YG
authors.lastname: Li
authors.forename: M
authors.initials: M
authors.lastname: Zabel
authors.forename: J
authors.initials: J
authors.lastname: Peetermans
authors.forename: R J
authors.initials: RJ
authors.lastname: Cohen
mesh_terms: D000328:Adult; D000368:Aged; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D004562:Electrocardiography / Q000379:methods* / Q000592:standards; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006321:Heart / Q000503:physiopathology*; D006334:Heart Function Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D012307:Risk Factors; D013610:Tachycardia / Q000503:physiopathology*; D017180:Tachycardia, Ventricular / Q000503:physiopathology* / Q000517:prevention & control* / Q000628:therapy; D014693:Ventricular Fibrillation / Q000503:physiopathology* / Q000517:prevention & control* / Q000628:therapy